Quote:
Originally Posted by johnt
The article is based on a paper written by Gendelman et al.. They write [1]:
The sample size is small: 10 active and 10 placebo. In Figure 4 there are two graphs, one showing the UPDRS III scores of the placebo group and the other the active group. To my eyes even before the treatment is started these groups have different properties.
John
|
Yes, the graphs certainly had some odd differences, and the sample size was small. Nevertheless, for a phase 1 safety and proof of concept study, this trial really was well designed and the results certainly have me interested in seeing a larger phase 2.